NR3C1 and cancer: In Figure 4C, among the statistically significant treatments that showed greater than median cytotoxicity across treatment dose concentrations (N = 7633), glucocorticoid receptor agonists (81), vitamin D receptor agonists (58), tubulin polymerization inhibitors (52), bromodomain inhibitors (49), and aurora kinase inhibitors (47) were the most common MOAs in the PRISM dataset when associated with cancer type and aneuploidy (Supplemental Tables S7 and S8).